Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Overview

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Overview

Add to Favorite
Added to Favorite


Positive Analyst Outlook: The consensus price target for Ionis Pharmaceuticals has seen a slight increase, indicating a positive outlook from analysts.
Anticipated Earnings Beat: Ionis is expected to surpass earnings estimates in its upcoming report, suggesting strong performance factors.
Revenue Growth Potential: Despite current financial challenges, Ionis anticipates significant revenue growth from upcoming drug approvals.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a biotechnology company that specializes in RNA-targeted therapeutics. Their product lineup includes SPINRAZA, a treatment for spinal muscular atrophy, and TEGSEDI, used for hereditary transthyretin-mediated amyloidosis. Ionis is also advancing several medicines in phase 3 clinical trials, showcasing their commitment to addressing various medical conditions.

The stock’s consensus price target has shown a slight upward trend over the past year. Initially, the average price target was $60.6, which increased to $65 in the last quarter and has remained steady. This stability suggests a positive outlook from analysts, likely due to Ionis’ ongoing developments and strategic partnerships with major pharmaceutical companies like Biogen Inc. and AstraZeneca.

Ionis Pharmaceuticals is expected to surpass earnings estimates in its upcoming report, as highlighted by Zacks. This expectation is based on the company’s strong combination of key factors that typically lead to an earnings beat. RBC Capital has set a price target of $64, indicating potential for the stock to move higher, reflecting confidence in Ionis’ future prospects.

Despite experiencing weak commercial revenues and significant losses, Ionis has five FDA-approved drugs and anticipates substantial revenue growth from upcoming drug approvals. The company is particularly optimistic about Wainua for ATTR-CM and Olezarsen for SHTG, which are expected to drive significant revenue increases. Ionis’ antisense and siRNA technologies have the potential to produce drugs with multi-billion dollar peak revenues nearing commercial approval.

Ionis Pharmaceuticals benefits from a diverse revenue stream, including collaborative and research and development revenues. This financial foundation allows the company to invest in advancing its wholly-owned drug pipeline. The recent Q2 2024 earnings conference call, featuring key company figures and prominent analysts, highlighted Ionis’ financial performance and future strategies, reinforcing the confidence in its market position and growth prospects.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Payoneer Global Inc. (NASDAQ:PAYO) Surpasses Q3 Earnings and Revenue Estimates

Payoneer's earnings per share (EPS) of $0.11 exceeded both...

Napco Security Technologies’ Financial Performance in the Competitive Market

Napco Security Technologies, Inc. (NASDAQ:NSSC) demonstrates strong capital efficiency...

The Bank of N.T. Butterfield & Son Limited (NYSE:NTB) Financial Overview

NTB's ROIC is significantly higher than its WACC, indicating...

Celsius Holdings Inc. (NASDAQ:CELH) Surpasses EPS Estimates but Misses on Revenue

Celsius Holdings Inc. (NASDAQ:CELH) reported EPS of $0.04276, beating...